CHRNA5-A3-B4 variants, rs16969968, rs588765 and rs578776, are consistently associated with tobacco consumption among smokers, but the association with smoking cessation is less consistent. Among the studies that reported significant associations with cessation, the effects were observed in smokers treated with placebo treatment in some studies and conversely in those receiving active pharmacological therapy (bupropion and nicotine replacement therapies) in others. Thus, it remains unclear whether CHRNA5-A3-B4 is a useful marker for optimizing smoking cessation. Using data from 654 Caucasian smokers treated with placebo, nicotine patch or varenicline, we investigated whether CHRNA5-A3-B4 variants were associated with smoking cessation outcomes, and whether there were significant genotype-by-treatment or haplotype-by-treatment interactions. We observed no significant associations between CHRNA5-A3-B4 variants and smoking cessation, despite replicating previous associations with baseline tobacco consumption. At end of treatment the effect size on smoking cessation in the placebo, patch and varenicline groups for rs16969968 [GG vs. GA+AA] Data Availability Statement: Data are from the PNAT2 study whose authors may be contacted at r. tyndale@utoronto.ca for data requests, pending ethical approval.
Introduction
Smoking is a leading cause of premature death; world-wide about 6 million deaths each year can be attributed to smoking [1] . Compared to never smokers, smokers' life expectancy is reduced by an average of 10 years [2] . Nicotine is the main psychoactive component of tobacco and exerts its pharmacological effects by its actions on the nicotinic acetylcholine receptors [3] . Genetic variants in CHRNA5-A3-B4, encoding the α5, α3, and β4 nicotinic acetylcholine receptor subunits, are robustly associated with smoking behaviors such as cigarettes smoked per day and nicotine dependence, as well as risks for smoking-related diseases, including lung cancer and chronic obstructive pulmonary disease [4] [5] [6] [7] [8] [9] [10] . Genetic mapping studies indicate that three independent loci within CHRNA5-A3-B4 are associated with cigarette consumption and nicotine dependence in Caucasians [11, 12] . These independent loci can be represented by rs16969968 and correlated SNPs (sometimes referred to as "Bin A" or "Locus 1"), rs588765 and correlated SNPs (sometimes referred to as "Bin B" or "Locus 3"), and rs578776 and correlated SNPs (sometimes referred to as "Bin C" or "Locus 2"). The impact of these independent loci on cigarette consumption and nicotine dependence has been consistently replicated, but whether these variants also predict smoking cessation outcomes is less clear and is the focus of this investigation [11, 12] .
Smoking cessation at any age has tremendous health benefits. Smokers who had quit smoking at 30, 40 and 50 years of age gained an average of 10, 9, and 6 years of life, respectively, when compared with those who continued to smoke [2] . Yet despite the substantial health benefits, only 3% of all smokers are able to quit smoking each year [3] . Of the three FDA-approved smoking cessation treatments [1] , transdermal nicotine patch delivers nicotine to reduce craving and withdrawal in smokers to promote smoking cessation. It is a commonly used treatment with few side effects, but it has modest clinical efficacy. Varenicline, a partial agonist for the α4β2 nicotinic receptor and a full agonist for the α7 nicotinic receptor [13] , appears to have the greatest clinical efficacy, but it has more side effects, such as nausea, which can lead to discontinuation of use. Substantial individual variability is observed in both clinical efficacy and in side effects within each type of smoking cessation treatment; genetics could contribute to this variability [14] [15] [16] . The estimated heritability of smoking cessation is 50-58% indicating that genetic factors are important determinants of cessation [14, 17] . Genetically tailored drug therapy could assist in maximizing smoking cessation efficacy. For example, the Pharmacogenomics of Nicotine Dependence Treatment (PNAT) clinical trial demonstrated that varenicline was more efficacious than nicotine patch for smokers with genetically normal rates of nicotine medication and placebo, as well as support for medication packaging, from Pfizer. She has also consulted to Gilead, and has been a paid expert witness in litigation against tobacco companies. Cinciripini served on the scientific advisory board of Pfizer Pharmaceuticals, conducted educational talks sponsored by Pfizer on smoking cessation from [2006] [2007] [2008] , and has received grant support from Pfizer. Schnoll received medication and placebo free of charge from Pfizer for a different project, and has consulted to Pfizer and GlaxoSmithKline. George has had both investigator-initiated and industry-sponsored grants from Pfizer in the past 12 months, and serves on a Data Monitoring Committee for Novartis. Benowitz has served as a consultant to several pharmaceutical companies that market smoking cessation medications and has been a paid expert witness in litigation against tobacco companies. Tyndale has acted as a consultant to pharmaceutical companies, primarily on smoking cessation. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The remaining authors report no conflicts of interest. metabolism, while the efficacy was equivalent for smokers with genetically slower rates of nicotine metabolism. Smokers with slower rates of nicotine metabolism (vs. smokers with normal rate of nicotine metabolism) also had higher overall side-effect severity when taking varenicline in comparison to placebo; together this suggests that normal metabolizers should be treated with varenicline, while slow metabolizers should be treated with nicotine patch [18] .
A number of studies have investigated the association between CHRNA5-A3-B4 gene variants and smoking cessation with inconsistent results. Some studies observed significant associations between CHRNA5-A3-B4 gene variants and smoking cessation [19] [20] [21] [22] [23] , while other studies did not [24] [25] [26] [27] [28] [29] , and a large genome-wide association study did not find a significant association between CHRNA5-A3-B4 gene variants and smoking status (i.e. current versus former smokers) [5] . Even among those studies reporting a significant association between CHRNA5-A3-B4 gene variants and smoking cessation, it is not clear whether the CHRNA5-A3-B4 SNPs have a general effect on smoking cessation, which is independent of the specific type of pharmacological treatment (i.e., would alter all active treatments), or whether they alter the efficacy of a specific treatment arm (i.e. only nicotine patch or placebo). For example, Chen and colleagues reported that the association between a CHRNA5-A3-B4 haplotype, the rs16969968_rs588765, consisting of rs16969968 (Bin A) and rs680244/rs588765 (Bin B), and smoking cessation was primarily observed among smokers treated with placebo; and that this association was mitigated by active pharmacological therapy [30] . In contrast, Munafò and colleagues reported a significant association between CHRNA5-A3-B4 variant rs1051730 (Bin A) and smoking cessation outcomes in smokers who were receiving nicotine replacement therapy, with little effect observed in those receiving placebo treatment [21] . Another recent study reported a significant treatment (placebo vs. nicotine replacement therapy) by genotype (rs1051730) interaction on smoking cessation outcomes [31] .
The objective of this study was to investigate the association between CHRNA5-A3-B4 gene variants and the clinical efficacy (i.e. smoking cessation outcomes) associated with treatment with placebo, nicotine patch or varenicline. This pharmacogenomics trial is the first to compare the impact of CHRNA5-A3-B4 gene variants on smoking cessation outcomes in these two widely used treatments head-to-head while including a double-dummy placebo controlled design. Further, the placebo treatment arm (N = 212) is larger than that included in the prior report identifying significant associations with CHRNA5-A3-B4 gene variants and smoking cessation under placebo treatment (N = 132) [30] . If these SNPs are validated in the current trial as significantly associated with an active treatment, it could be possible to optimize the choice of pharmacotherapy for individual smokers based on genotype or haplotype. We first sought to confirm the significant effect of the CHRNA5-A3-B4 variants on baseline smoking behaviors in the screened Caucasian population (N = 1026), and then to investigate the association between these CHRNA5-A3-B4 SNPs and smoking cessation in 654 Caucasian smokers randomized to placebo, nicotine patch or varenicline. We focused on the Caucasians participants of the clinical trial in this analysis to minimize population stratification.
Methods

Participants and procedures
Smokers were recruited into a placebo-controlled clinical trial through advertisements for a free smoking cessation program. The primary findings of this clinical trial were recently published [18] . The study consisted of three treatment arms: (1) nicotine patch (placebo pill/active patch); (2) varenicline (active pill/placebo patch); and (3) placebo (placebo pill/placebo patch). The present genetic analyses were restricted to Caucasian smokers to minimize population stratification as the frequency of these variants varies substantially between world populations.
Caucasian smokers (N = 1026) were screened for their rate of nicotine metabolism (based on their nicotine metabolite ratio) and baseline smoking phenotypes. Of this group, 654 Caucasian smokers were randomized into the three treatment arms with slow metabolizers oversampled to assess the influence of nicotine metabolism on smoking cessation [18] . The over-sampling of smokers with slow nicotine metabolism is unlikely to introduce bias into our analyses of CHRNA5-A3-B4 and smoking cessation since the allele frequencies of the CHRNA5-A3-B4 SNPs observed in this study were very similar to allele frequencies reported by previous studies in Caucasians as well as by the 1000 genome project (see results) [11, 12, 30] . Furthermore, the gene encoding for the main nicotine metabolizing enzyme, CYP2A6, is on a different chromosome than CHRNA5-A3-B4, and is thus unlikely to have any linkage equilibrium relationship with CHRNA5-A3-B4. There was also little difference in the results with or without adjusting for the rate of nicotine metabolism in any of the smoking cessation models.
The clinical trial was conducted at four academic medical centers (University of Pennsylvania, Centre for Addiction and Mental Health/University of Toronto, State University of New York at Buffalo, and MD Anderson Cancer Center). Eligible participants were 18-65 years old and reported smoking 10 cigarettes per day for 6 months (verified by carbon monoxide (CO) > 10ppm). Exclusion criteria included use of non-cigarette tobacco products; history of substance abuse treatment (other than nicotine); consumption of more than 25 standard alcohol drinks per week; history of DSM-IV Axis 1 psychiatric disorder or suicide risk score on the MINI International Neuropsychiatric Interview; history of cancer, kidney or liver diseases; history of clinically significant cardiac dysrhythmias, stroke, angina, heart attack, or uncontrolled hypertension; use of smoking cessation medication within the last 14 days; current use of anti-psychotics, stimulants, opiate medications, anti-coagulants, rescue inhalers, or antiarrhythmics; and pregnancy/ lactation. The study protocol has been published previously [18] . Briefly, intention-to-treat smokers were randomly assigned by baseline NMR status to 11 weeks of placebo (placebo pill plus placebo patch), 21 mg nicotine patch (active patch plus placebo pill), or 1 mg varenicline (active pill plus placebo patch), plus behavioral counselling. The primary endpoint was biochemically verified 7 day point prevalence abstinence at the end of treatment to estimate the pharmacological effect of treatment by NMR. All participants provided written informed consent in accordance with the principles expressed in the Declaration of Helsinki, and the study protocol was approved by the institutional review boards of University of Pennsylvania, University of Toronto, State University of New York at Buffalo, and MD Anderson Cancer Center.
Smoking abstinence
Biochemically verified 7-day point prevalence abstinence was assessed at end of treatment (EOT, week 11), 6 months and 12 months. Point prevalence abstinence is defined as no-self-reported smoking (not even a puff) for at least 7 days and was verified by exhaled carbon monoxide levels < 8 ppm [32] . We focused on the EOT time point in the present study as we were interested in the pharmacogenetic effect of CHRNA5-A3-B4 variants on smoking cessation, which is strongest during treatment; as in most pharmacogenomics studies this was the primary time point used for analysis of these gene variants [21, 23, 30, 31] ; we have also included 6 month and 12 month smoking abstinence association data in supplementary materials. All statistical analyses on smoking cessation were performed on an intent-to-treat basis; subjects lost during follow-up were considered as smokers [32] .
genotyping reaction was performed with 2.5 μL TaqMan GTXpress master mix and 2.5 μL of water containing 10 ng of DNA and 0.0625 μL of 80x Taqman SNP genotyping probes (rs16969968: C__26000428_20, rs588765: C____18826_10 and rs578776: C____721253_10, Applied Biosystems, Foster City, CA). The allele discrimination data were analyzed using Viia 7 software version 1.2. All genotyping results included in our analyses had call quality values >0.985. For quality control (QC) all samples were genotyped again using a second independent DNA sample for two high allele frequency variants (rs16969968 & rs588768), and~18% of the samples (n = 180) were also re-genotyped for rs578776. The concordance rates for all SNPs between the original genotyping and the QC genotyping were 100%.
PLINK was used to estimate CHRNA5-A3-B4 haplotype (rs16969968 and rs588765) probabilities for each individual (using the-hap-phase-wide option) as described previously [30, 33] . The posterior probability for the haplotypes was 1 for more than 99% of the haplotypes. The haplotypes were assumed to be 'additive' [30] .
Nicotine metabolism
This clinical trial was design to prospectively assess the impact of nicotine metabolism on smoking cessation outcomes. The rate of nicotine metabolism was assessed in a baseline blood sample by the nicotine metabolite ratio (NMR; 3'hydroxycotinine/cotinine). NMR is highly reproducible in regular smokers, shows little temporal fluctuation due to the long half-life of cotinine (16 hours) [34, 35] , and is not influenced by variation in other cotinine or 3-hydroxycotinine metabolizing genes, but rather exclusively by CYP2A6 [36] . The NMR used to distinguish slow metabolizers from normal metabolizers was 0.31 based on the stratification performed in the parent clinical trial [18] . Individuals with slower rates of nicotine metabolism were over-sampled to increase statistical power, therefore, in the current analyses we performed analyses with and without adjusting for the rate of nicotine metabolism (as a covariate) in all the smoking cessation models. Thus these models examined both the role of the nicotinic receptor variants alone, and with the CYP2A6 phenotype as previously described [37] . Additional baseline measures assessed included self-report cigarettes per day, cotinine levels, derived cotinine per cigarette and Fagerstrom test for nicotine dependence (FTND).
Analytical chemistry
Concentrations of cotinine and 3-HC were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described previously [38, 39] . Briefly, 100 μL biological samples were extracted using a liquid-liquid extraction with cotinine-d 3 and 3-hydroxycotinine-d 3 as the internal standards. The evaporated extract was reconstituted in 100 μL of 100 mM aqueous ammonium acetate: methanol (v/v 80:20) with 1% acetic acid [38, 39] . The chromatography was carried out using a Synergi Polar RP column (150 x 4.6 mm I.D.; particle size 4 micron). A linear gradient of 10 mM ammonium acetate/0.1% acetic acid in water (solvent A) and 10 mM ammonium acetate/0.1% acetic acid in methanol (solvent B) was used as the mobile phase [38, 39] . At a flow rate of 0.7 ml/min. 3-HC and cotinine eluted at 5.3 and 6.2 min, respectively. Calibration standards were prepared in the range of 1 to 1000 ng/mL, unlabeled standards were plotted against fixed concentration (20 ng/ml) of corresponding labeled internal standard. The plots were linear for cotinine and 3HC with r 2 > 0.99 for both. Cotinine's molecular weight is 176.21g/mol. Thus, 1 ng/ml cotinine = 5.67 nmol/L.
Statistical analyses
Baseline demographic variables among the total screened population were compared between CHRNA5-A3-B4 genotypes using Mann-Whitney tests, Kruskal-Wallis tests, or Chi-square tests. The associations between dichotomized CHRNA5-A3-B4 SNPs rs16969968 (G/G = 0 and G/A and A/A = 1), rs588765 (C/C = 0 and C/T and T/T = 1), and rs578776 (A/A = 0 and A/G and G/G = 1) and smoking abstinence were evaluated using logistic regression among the intent to treat population. All smoking cessation models were adjusted for age, gender and rate of nicotine metabolism as covariates (see figure legends for details). The CHRNA5-A3-B4 haplotypes were dummy coded (i.e., each individual would have variables for haplotype 1, haplotype 2 and haplotype 3). Statistical analyses were performed using Stata 12 (StataCorp, College Station, TX).
Results
Descriptive data of the study participants
Demographic data for the screened population are presented in Table 1 ). The SNPs rs16969968, rs588765 and rs578776 had minor allele frequencies of 39.3%, 40.0% and 25.0% respectively in the screened population (N = 1026), which were very similar to 37.3%, 41.7% and 25.2% in the intent-to-treat participants (N = 654). These allele frequencies were also very similar to published frequencies in Caucasians (e.g. Saccone et al., 2010 reported 42%, 39% and 24% respectively [12] , and the 1000 genome project reported 41.7%, 39.2% and 24.2% respectively) [4, 5, 11, 12, 30, 40] . CHRNA5-A3-B4 haplotypes were constructed using rs16969968 and rs588765 [30] . In this study, the rs16969968_rs588765 haplotype frequencies were G_C 20.9%, G_T 40.0%, and A_C 39.2%, which is very similar to the 20.8%, 43.7% and 35.5% reported previously [30] . Those were labeled haplotype 1, haplotype 2, and haplotype 3 respectively [30] .
Association between CHRNA5-A3-B4 genetic variants and cigarettes consumption rs16969968. Among the screened participants, the 'A' allele of rs16969968 was significantly associated with 10% higher cotinine levels (per allele effect = 23.9 ng/mL, CI = 14.4-33.4, P<0.0001, Fig 1A) , but not significantly with self-reported cigarettes per day (P = 0.30, Table 1 and Fig 1B) . A significant association between rs16969968 and cotinine was also observed in the intent-to-treat participants (per allele effect = 22.4 ng/mL, CI = 6.7-38.1, P = 0.005). Interestingly, adjusting for self-reported cigarette consumption very modestly reduced the per allele effect of rs16969968 on cotinine (the per allele effect size of rs16969968 on cotinine was 21.8, CI = 12.6-30.9, P<0.0001 after adjusting for cigarettes per day versus the 23.9 ng/mL without adjustment, Fig 1C) , indicating the weakness of self-reported consumption relative to cotinine as a measure of consumption. This suggests that smokers with the 'A' allele of rs16969968 likely extracted more nicotine per cigarette, which is supported by the observation that smokers with the 'A' allele of rs16969968 had significantly higher cotinine per cigarette (P = 0.002, Fig 1C) . The association between rs16969968 and smoking behaviors did not differ significantly by gender (data not shown) as previously observed [4] [5] [6] [7] 41] .
rs588765. Among the screened participants, rs588765 was not significantly associated with cigarettes per day, cotinine levels, or cotinine per cigarette (Table 1 and S1 Fig) . Adjusting for rs16969968 did not significantly alter the association between rs588765 and smoking phenotypes (data not shown). rs578776. Among the screened participants, the 'A' allele of rs578776 was significantly associated with 8% lower cotinine levels (per allele effect is -18.9 ng/mL CI = -29.7 --8.2, P = 0.002, Table 1 and S2 Fig), but not significantly associated with cigarettes per day (P = 0.53, Table 1 and S2 Fig) . Adjusting for self-reported cigarette consumption did not substantially reduce the per allele effect size of rs578776 on cotinine levels (the per allele effect size of rs578776 was -18.4 ng/mL, CI = -28.8 --8.1, P<0.0001 versus the -18.9 ng/mL without adjustment, S2  Fig) . However, the association was no longer significant after adjusting for rs16969968 (the per allele effect size was -8.2 ng/mL, CI = -20.24-3.93, P = 0.19 versus the -18.9 ng/mL without adjustment).
Haplotype analyses. Among the screened participants, cigarettes per day and FTND levels did not significantly differ between the CHRNA5-A3-B4 haplotypes (Table 2) . However, haplotype 3 was significantly associated with lower cotinine levels compared to haplotype 1 (Table 2, P<0.0001). Association between CHRNA5-A3-B4 SNPs and haplotype with smoking cessation
We next investigated the association between CHRNA5-A3-B4 variants and smoking abstinence in the intent-to-treat group (N = 654). Overall at EOT, 19.8% of the participants (42 out of 212) receiving the placebo treatment were abstinent, 24.8% of the participants (55 out of 222) receiving the nicotine patch treatment were abstinent, and 38.6% of the participants (85 out of 220) receiving the varenicline treatment were abstinent.
rs16969968. Smoking abstinence rates by rs16969968 genotype are shown in Fig 2.  rs16969968 was not significantly associated with smoking abstinence in the total (adjusting for treatment arm), placebo, nicotine patch, or varenicline groups (total odds ratio (OR) = 1.00, 95% CI = 0.70-1.42 and P = 0.99, placebo OR = 0.66, 95% CI = 0.33-1.31 and P = 0.23, patch OR = 1.01, 95% CI = 0.54-1.88 and P = 0.99, or varenicline OR = 1.30, 95% CI = 0.74-2.28 and P = 0.36). There were no significant two-way genotype-by-treatment interactions (S1 Table) . These results were not altered substantially when adjusting for the rate of nicotine metabolism (dichotomized as NMR<0.31 and 0.31 [18] ), age, sex, and baseline cigarette consumption (Fig 2) . All models were adjusted for age and gender. NMR = nicotine metabolite ratio.
The CHRNA5-A3-B4 haplotype was defined by rs16969968 and rs588765. * Cotinine is a part of NMR, and cotinine levels are not directly comparable in people with different NMR [48] , thus NMR was not included in the cotinine analysis. Table) . These results were not altered substantially when adjusted for the rate of nicotine metabolism, age, sex, and cigarette consumption (Fig 3) .
rs578776. Smoking abstinence rates by rs578776 genotype are shown in Fig 4. rs578776 was not significantly associated with smoking abstinence in the total (adjusting for treatment arm), placebo, nicotine patch, or varenicline groups (total OR = 0.98, 95% CI = 0.69-1.40 and P = 0.93, placebo OR = 1.02, 95% CI = 0.52-2.02 and P = 0.95, patch OR = 0.75, 95% There were no significant genotype-by-treatment interactions (S3 Table) . These results were not altered substantially when adjusted for the rate of nicotine metabolism, age, sex, and cigarette consumption (Fig 4) .
Haplotype analyses. Smoking abstinence rates by rs16969968_rs588765 haplotype are shown in Fig 5. In logistic regression models, haplotype 2 (G_T) and haplotype 3 (G_C) were not significantly associated with smoking abstinence within each treatment group independently compared to the reference haplotype 1 group (G_C) (OR = 0.74-1.16, P>0.05). Furthermore, the haplotypes did not predict abstinence in the entire study group, and no significant haplotype-by-treatment interactions were observed (Table 3 and S3 Fig.) .
6 month and 12 month smoking abstinence. CHRNA5-A3-B4 variants rs16969968, rs588765, & rs578776 were not significantly associated with smoking abstinence at 6 month and 12 month follow-up (ORs range from 0.54 to 1.98, P values range from 0.11 to 0.92, S4 Table) . Similarly, rs16969968_rs588765 haplotypes were not significantly associated with smoking abstinence at 6 month and 12 month follow-up (S5 and S6 Tables).
Discussion
In this study, we report a lack of association between CHRNA5-A3-B4 genetic variants/haplotype and end of treatment smoking cessation outcomes in Caucasian smokers despite the expected significant association between CHRNA5-A3-B4 genetic variants and baseline smoking behaviors (cotinine levels). Our study is the first placebo-controlled clinical trial investigating the association of CHRNA5-A3-B4 genetic variants with smoking cessation during treatment with the nicotine patch versus varenicline. We observed no significant CHRNA5-A3-B4 The association between rs578776 and smoking abstinence in Caucasian smokers. (a) Rs578776 was not associated with smoking abstinence in smokers treated with placebo. Adjusting for NMR, sex and age did not significantly alter the association (OR adjusted = 1.00, P adjusted = 0.99). (b) Rs578776 was not associated with smoking abstinence in smokers treated with nicotine replacement patch. Adjusting for NMR, sex and age did not significantly alter the association (OR adjusted = 0.74, P adjusted = 0.35). (c) Rs578776 was not associated with smoking abstinence in smokers treated with varenicline. Adjusting for NMR, sex and age did not significantly alter the association (OR adjusted = 1.14, P adjusted = 0.63). The black lines represent the average abstinence rate between the GA and AA group. Statistical significance was evaluated using dominant models (i.e. GG = 0 and GA/AA = 1). OR = odds ratio. NMR = nicotine metabolite ratio. GG, GA, & AA represent different genotypes of rs578776. Lack of Associations between CHRNA5-A3-B4 and Smoking Cessation genotype-by-treatment interactions with or without adjusting for the rate of nicotine metabolism (i.e. CYP2A6 activity). Together, these findings would not support the use of CHRNA5-A3-B4 genetic variants to optimize smoking cessation pharmacotherapy selection in Caucasian smokers. Our findings are in agreement with previous large genome-wide association studies which reported that CHRNA5-A3-B4 variants on chromosome 15 are associated with tobacco consumption among smokers but not smoking status (i.e., current smoker vs. former smoker, n = 41,278), indicating CHRNA5-A3-B4 variants are not associated with smoking cessation [5] . Our findings also agree with the conclusions of the Munafò and colleagues study, which suggested the clinical significance of CHRNA5-A3-B4 genetic variants on smoking cessation was limited [21] .
On the other hand, our findings are in contrast to those findings reported by Chen and colleagues and Bergen and colleagues, who reported significant associations between CHRNA5-A3-B4 haplotype and smoking cessation in smokers who received placebo treatment [30, 31] . It is worth noting that both of these previous studies were partial secondary analyses of an overlapping clinical trial sample, which had significant heterogeneity in the active treatment group (they had 5 distinct active treatments) and Chen et al., had a relatively small placebo group (n = 132) in contrast to n = 212 in the current study [18] . However, since the CHRNA5-A3-B4 associations with smoking cessation were primarily observed in their placebo group, it is unclear why the findings differed between our study and these past studies. The current lack of association between CHRNA5-A3-B4 and smoking cessation was not influenced by the rate of nicotine metabolism (i.e. adjusting for NMR) and a follow-up study by Chen and colleagues reported that CHRNA5-A3-B4 and CYP2A6 genotype estimated rate of nicotine metabolism were independent signals [37] . Together this suggests that it is unlikely that the lack of association between CHRNA5-A3-B4 and smoking cessation observed in the current study is related to differences in nicotine metabolism.
Smoking cessation is an important and complex smoking phenotype; genetic factors are one of many factors which can influence smoking cessation. One possibility for the discrepancy is the variability in participant demographics across studies. The clinical trial reported in past studies consisted of 58% females, whereas our study had 42% females. All studies followed All models were adjusted for age, gender and nicotine metabolism.
The CHRNA5-A3-B4 haplotype was defined by rs16969968 and rs588765 as previously defined [30] .
doi:10.1371/journal.pone.0128109.t003
available guidelines for pharmacotherapy administration. However, it is possible that the content or intensity of behavioral counseling differed across studies. If such contextual factors could alter genetic association results, then it could be argued that the genetic findings are unlikely to be sufficiently robust for use in clinical practice.
To demonstrate potential clinical utility in treatment decision-making, a significant geneby-treatment interaction is important; however, we did not observe any evidence or trends in this regard. Recently we have reported that varenicline is more efficacious than nicotine patch in smokers with a faster rate of nicotine metabolism in contrast to smokers with a slower rate of nicotine metabolism [18] . Hence, the rate of nicotine metabolism can be used to predict the most efficacious type of smoking cessation therapy. In the case of CHRNA5-A3-B4 variants, the existing literature is conflicting, lacking a consistent genotype-by-treatment interaction [19-21, 30, 31] . Therefore, it is unlikely that CHRNA5-A3-B4 can be used clinically to predict the most effective smoking cessation pharmacotherapy.
Our conclusions should be interpreted in the context of statistical power. However, in the model of cessation in the full sample of 654 individuals adjusting for treatment arm, the ORs for the CHRNA5-A3-B4 variants differed very little from 1, suggesting no trends for association. For a treatment arm specific effect, at the current samples size (n = 212 to 222 per arm), we are at 0.8 power to detect any effect size larger than OR =~2.3 for any genetic variants with a 40% allele frequency. Therefore, our data can statistically support that CHRNA5-A3-B4 variants do not have a large impact on smoking cessation. Although it is possible that our study was not sufficiently powered to reject a weak association between CHRNA5-A3-B4 variants and smoking cessation, the absence of clinically meaningful trends in our study and the lack of genotype-by-treatment interactions reported by previous studies would still support our conclusion.
In contrast to the inconsistent reports on associations with cessation, gene variants in CHRNA5-A3-B4, particularly rs16969968 and correlated SNPs, have been consistently associated with tobacco consumption in Caucasian smokers [4-7, 11, 12] . In this study, we observed a significant association between rs16969968 and cotinine levels. The 'A' allele of rs16969968 was associated with a roughly 23.9 ng/ml increase in cotinine per allele. These effect sizes were within the previously reported range of 24-100 ng/ml per allele [42] [43] [44] . In contrast, we did not observe any significant association between CHRNA5-A3-B4 variants and cigarettes per day despite the significant association between nicotine metabolism rate and cigarettes per day. A number of previous studies have also found that the rate of nicotine metabolism has a greater influence on cigarette consumption (i.e. cigarettes smoked per day, total nicotine equivalents) compared to CHRNA5-A3-B4 gene variants [44, 45] . Thus, it is interesting that CHRNA5-A3-B4 variants generally have a greater effect on lung cancer risk than variation in nicotine metabolism [45] . This observation suggests that the CHRNA5-A3-B4 gene variants may modulate lung cancer risk by mechanisms in addition to their effects on smoking behavior, such as directly altering cell proliferation and survival [46] . This hypothesis could be directly tested by measuring better tobacco consumption biomarkers (such as urinary total nicotine equivalents) in lung cancer epidemiology studies [42, 47] .
In conclusion, the findings of our study, in conjunction with some previous reports, demonstrated a lack of CHRNA5-A3-B4 genotype by active smoking cessation pharmacotherapy interaction in smokers, and no effect within any treatment arm including placebo. Thus these current and previous data together suggest that it is unlikely that CHRNA5-A3-B4 could be used clinically to predict the most effective smoking cessation pharmacotherapy to offer to the individual smoker seeking to quit. Table. The association between CHRNA5-A3-B4 variants and 6 month and 12 month smoking abstinence in the intent to treat population (N = 654) (DOCX) S5 Table. The association between CHRNA5-A3-B4 Haplotype and 6 month smoking abstinence in the intent to treat population (N = 654). (DOCX) S6 Table. The association between CHRNA5-A3-B4 Haplotype and 12 month smoking abstinence in the intent to treat population (N = 654). Author Contributions
